Advances in Wound Care to Boost Diabetic Ulcers Treatment Market
Published On : Jun 04, 2019 | Category : Healthcare
Chronic wounds have had a major socio-economic effect. Chronic injuries usually require longer healing and advanced treatment for wounds. Wound healing is usually an inherent mechanism. Some metabolic disorders, such as diabetes mellitus, however, delay the typical rate of wound healing. Ulcers are formed due to a combination of factors like foot lack, poor circulation, deformities in the foot, irritation (for example rubbing or pressure) and trauma as well as diabetes duration.
Neuropathic diseases, reduced or total lack of the ability to feel pain of feet due to nerve damages caused by elevated levels of blood glucose can occur in patients with diabetes for many years. For diabetic ulcers the best possible treatment for wound management is essential. Clinicians must be fully aware of the wound, cause, risk, progression, and treatment for the most effective treatment of diabetic foot and pressure ulcers. The major challenges for proper treatment of diabetics ' foot ulcers and pressure ulcers are the high chances of recurrence of the cured pressure and foot ulcer and high mortality. This is likely to drive over the estimated time period the global market for diabetics.
Growing Incidence of Diabetes to Propel Diabetic Ulcer Treatment Market
The incidence of Type I and maturity-induced diabetes is becoming more common in developed countries worldwide. Chronic wounds have had a major socio-economic impact. Chronic wounds usually require more time to cure and advanced wound treatments. Furthermore, research by NCBI says that global prevalence of diabetic foot ulcer is 6.3% higher in males than women (4.5%) (3.5%). The NCBI also reports a global prevalence of diabetic foot ulcer. A leg is amputated globally every 30 seconds by diabetic foot ulcer. Diabetic foot ulcer risk is 25 per cent for a lifetime among the people with diabetes. Thus, the worldwide diabetic ulcer treatment market is expected to increase the prevalence of diabetic foot ulcers.
The introduction of novel therapeutics in wound care is expected to create ample opportunities for vendors in the global diabetic ulcers treatment market. The use of topical ointments and sprays is likely to propel sales in the global market. ViroMed, in August 2017, began third phase of trials for VM202 gene therapy. This therapy focuses on concomitant peripheral artery disease, and diabetic foot ulcers. Further, the USFDA approved the marketing of SANUWAVE Health’s Dermaspace System, which is the first of its kind of shock wave device for treating diabetic foot ulcers. Advancements in NPWT therapy devices, new biologic products, constant innovation, and research in skin grafts and growth factors are expected to propel the global market during the forecast period.
Asia Pacific to Emerge as High Potential Regional Market
The growing prevalence of diabetes and a large geriatric base support regional market growth in both India and China. In the advanced economies like Japan and Australia, this can also be explained by increased adoption and positive legislation. There are many under-served patients in emerging economies, such as India, China, Brazil, Mexico and South Africa, making Asia Pacific a potential emerging market. Market expansion in the region can be attributed to the emergence of strong local manufacturers, which offer technologically advanced products at a lower price and raise people's awareness of early diagnosis.
Prominent vendors operating in the global diabetic ulcers treatment market are ntegra Life Sciences Corporation, Smith & Nephew plc, 3M Healthcare, Hill-Rom Holdings, Inc., and B. Braun Melsungen AG.